Fred Hutchinson Cancer Center scientists have developed the first genetically human monoclonal antibodies capable of blocking Epstein-Barr virus (EBV), a pathogen that infects roughly 95% of the global population. Published February 17 in Cell Reports Medicine, the study identified antibodies targeting two key viral proteins — gp350 and gp42 — that prevent EBV from entering human immune cells.

In testing on mice with human immune systems, one antibody targeting gp42 completely blocked EBV infection, while another targeting gp350 provided partial protection. The team, led by biochemist Andrew McGuire and doctoral candidate Crystal Chhan, discovered a total of 10 antibodies — two against gp350 and eight against gp42.

The breakthrough is especially significant for the 128,000+ patients who undergo organ or bone marrow transplants annually in the U.S. These immunocompromised individuals face high risk of post-transplant lymphoproliferative disorder (PTLD), an aggressive EBV-driven cancer with no specific preventive therapy until now.